|
|
|
|
|
Procainamide
drug data and news
Procainamide drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Procainamide | ||
| Brand Names/Synonyms | Biocoryl; Novocainamid; Novocainamide; Novocaine Amide; Novocamid; Procainamide; Procainamide Hcl; Procaine Amide; Procamide; Procan; Procan Sr; Procanbid; Procapan; Promine; Pronestyl; Pronestyl-Sr | ||
| Indication | For the treatment of life-threatening ventricular arrhythmias | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Procainamide is an agent indicated for production of local or regional anesthesia and in the treatment of ventricular tachycardia occurring during cardiac manipulation, such as surgery or catheterization, or which may occur during acute myocardial infarction, digitalis toxicity, or other cardiac diseases. The mode of action of the antiarrhythmic effect of Procainamide appears to be similar to that of procaine and quinidine. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole. The sinoatrial node is, however, unaffected. | ||
| Mechanism Of Action | Procainamide is sodium channel blocker. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action. | ||
| Procainamide News (When available) |
| ||
| Dosage Forms | CAPSULE; LIQUID; SOLUTION; TABLET (EXTENDED-RELEASE) | ||
| Drug_Category | Antiarrhythmic Agents; ATC:C01BA02 | ||
| Absorption | 75 to 95% | ||
| Interactions |
Interactions for Procainamide: If other antiarrhythmic drugs are being used additive effects on the heart may occur with procainamide administration, and dosage reduction may be necessary. Anticholinergic drugs administered concurrently with procainamide may produce additive antivagal effects on A-V nodal conduction, although this is not as well documented for procainamide as for quinidine. Patients taking procainamide who require neuromuscular blocking agents such as succinylcholine may require less than usual doses of the latter, due to procainamide effects on reducing acetylcholine release. | ||
| Toxicity | LD50=95 mg/kg (rat, IV); LD50=312 mg/kg (mouse, oral); LD50=103 mg/kg (mouse, IV); LD50=250 mg/kg (rabbit, IV) | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 4-amino-N-(2-diethylaminoethyl)benzamide | ||
| Chemical Formula | C13H21N3O | ||
| Molecular Weight | 235.325 g/mol | ||
| Smiles String | CCN(CC)CCNC(=O)C1=CC=C(C=C1)N | ||
| Melting Point | 165-169 °C | ||
| Water Solubility | 5050 mg/L | ||
| State | Solid | ||
| LogP/Hphobicity | 1.282 | ||
| Isoelectric Point | 9.32 | ||
| Biotransformation | Hepatic | ||
| Half Life | ~2.5-4.5 hours | ||
| Protein Binding [%] | 15 to 20% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Procainamide.html http://www.rxlist.com/cgi/generic3/procain.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00509 | ||
| CAS Registry Number | 51-06-9 | ||
| KEGG Compound ID | C07401 | ||
| PubChem ID | SID:9605 | ||
| PharmGKB ID | PA451108 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 713341 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |